Development of a high-yield expression and purification system for platelet factor 4

Area of Science:

• Biochemistry
• Immunology
• Recombinant protein production

Background:

• Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction involving IgG antibodies against platelet factor 4 (PF4) and heparin.
• Current HIT diagnostic tests often require exogenous PF4, highlighting the need for reliable PF4 sources.

Purpose of the Study:

• To develop an efficient bacterial expression system for producing recombinant human PF4 (rhPF4).
• To ensure the produced rhPF4 is biochemically and antigenically comparable to platelet-derived PF4 for diagnostic applications.

Main Methods:

• Utilized a bacterial expression system (pET/BL21(DE3) E. coli) optimized for rhPF4 production.
• Employed various detergents, heparin affinity, and ion exchange chromatography for purification.
• Characterized rhPF4 using mass spectrometry, SDS-PAGE, gel filtration, anti-PF4/heparin EIA, and PF4-SRA.

Main Results:

• Successfully produced high yields of pure rhPF4 (11.4 mg/L) with improved solubility.
• rhPF4 demonstrated biochemical, antigenic, and functional similarity to platelet-derived PF4 in assays.
• High correlation (r=0.9545 for EIA, r=0.9597 for PF4-SRA) was observed between rhPF4 and platelet-derived PF4.

Conclusions:

• The developed bacterial expression method provides an efficient, platelet-independent source of rhPF4.
• This method offers higher yields and lower costs compared to existing techniques.
• The rhPF4 produced can enhance the efficiency of biochemical research and HIT diagnostic testing.